Physician profile
William E Tyson
NPI 1871988659
$2,159.44
in general payments reported to CMS, 2019-2025
16 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $510 · 2021: $582 · 2022: $325 · 2023: $80.05 · 2024: $149 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $540.87 | 2020-2021 | |
| Nevro Corp. | $373.94 | 2020-2022 | |
| Janssen Biotech, INC. | $336.68 | 2024-2025 | Tremfya, Stelara |
| Avanos Medical | $198.55 | 2020-2021 | |
| Medtronic, INC. | $162.28 | 2022 | |
| Allergan, INC. | $132.11 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $98.69 | 2022-2023 | Xtampza |
| Takeda Pharmaceuticals U.S.A., INC. | $57.20 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $52.19 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $44.75 | 2025 | Sucraid |
| Merck Sharp & Dohme LLC | $40.65 | 2024 | Dificid, Recarbrio, Zerbaxa |
| Lilly USA, LLC | $31.73 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $27.03 | 2024 | Voquezna |
| Ardelyx, INC. | $25.33 | 2025 | Ibsrela |
| Abbvie INC. | $23.79 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.